Technology
AstraZeneca, AI biologics firm Absci tie up on cancer drug
Anglo-Swedish drugmaker AstraZeneca has signed a deal worth up to $247 million with US artificial intelligence (AI) biologics firm Absci to design an antibody to fight cancer, Absci said in a statement on Sunday.
Absci's collaboration with AstraZeneca aims for a zero-shot generative AI model designed to create new and improved antibody therapeutics, the company said. It did not say what kind of cancer they plan to target.
Absci applies generative artificial intelligence to design optimal drug candidates based on target affinity, safety, manufacturability and other traits.
"We're proud to work closely with AstraZeneca to leverage our AI to bring novel treatments to oncology patients," Absci CEO Sean McClain said.
AstraZeneca did not immediately respond to a Reuters requests for comment.
The Financial Times, which first reported the deal, said it includes an upfront fee for Absci, research and development funding and milestone payments, and royalties on any product sales.
-
Technology10h ago
California’s Draft AI Law Would Protect More Than Just People
-
Technology10h ago
What’s Working: How a Colorado program is linking quantum, space and tech companies to a future workforce
-
Technology1d ago
AI 'hallucinations' can lead to catastrophic mistakes, but a new approach makes automated decisions more reliable
-
Technology2d ago
2 solar probes are helping researchers understand what phenomenon powers the solar wind
-
Technology2d ago
Robots are coming to the kitchen − what that could mean for society and culture
-
Technology2d ago
Mitochondria keep your brain cells alive − helping them run smoothly may protect against Parkinson’s disease
-
Technology2d ago
China's upgraded light-powered 'AGI chip' is now a million times more efficient than before, researchers say
-
Technology2d ago
New invention harvests ambient Wi-Fi and Bluetooth signals to power small devices